ULTRAGENYX PHARMACEUTI

Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease

30 Apr 2024 16:00:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

30 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update

25 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

19 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102

15 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome

12 Apr 2024 16:22:53 By Nasdaq GlobeNewswire

Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting

12 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

22 Mar 2024 16:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Participate at Investor Conferences in March

27 Feb 2024 16:30:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

23 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

15 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update

08 Feb 2024 16:00:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)

06 Feb 2024 08:00:01 By Nasdaq GlobeNewswire

Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome

05 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

25 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

19 Jan 2024 16:00:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones

07 Jan 2024 11:00:00 By Nasdaq GlobeNewswire

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

04 Jan 2024 08:00:29 By Nasdaq GlobeNewswire

Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome

03 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 16:05:00 By Nasdaq GlobeNewswire